H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 109 Citations 44,514 452 World Ranking 2514 National Ranking 108

Overview

What is she best known for?

The fields of study she is best known for:

  • Gene
  • Cancer
  • Internal medicine

Breast cancer, Cancer, Internal medicine, Cancer research and Genetics are her primary areas of study. The Breast cancer study combines topics in areas such as Odds ratio and Genome-wide association study, Genotype, Single-nucleotide polymorphism. The various areas that she examines in her Cancer study include Missense mutation, Basal and Case-control study.

Her Internal medicine research integrates issues from Endocrinology, Gynecology and Oncology. Irene L. Andrulis has researched Cancer research in several fields, including Gene expression, Mutation, Carcinogenesis, Germline and Gene. Quantitative trait locus is closely connected to Menarche in her research, which is encompassed under the umbrella topic of Genetics.

Her most cited work include:

  • Large-scale genotyping identifies 41 new loci associated with breast cancer risk (834 citations)
  • Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers (805 citations)
  • Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers (805 citations)

What are the main themes of her work throughout her whole career to date?

Irene L. Andrulis spends much of her time researching Breast cancer, Internal medicine, Oncology, Cancer and Genetics. Her Breast cancer study combines topics from a wide range of disciplines, such as Cancer research, Genome-wide association study, Genotype, Single-nucleotide polymorphism and Gynecology. The study incorporates disciplines such as Candidate gene, Genetic association, Bioinformatics and Genetic predisposition in addition to Genome-wide association study.

Ovarian cancer, Odds ratio, Hazard ratio, Estrogen receptor and Family history are among the areas of Internal medicine where she concentrates her study. Irene L. Andrulis usually deals with Oncology and limits it to topics linked to Germline mutation and Germline. Irene L. Andrulis is involved in the study of Cancer that focuses on Breast disease in particular.

She most often published in these fields:

  • Breast cancer (110.42%)
  • Internal medicine (60.26%)
  • Oncology (53.21%)

What were the highlights of her more recent work (between 2018-2021)?

  • Breast cancer (110.42%)
  • Internal medicine (60.26%)
  • Oncology (53.21%)

In recent papers she was focusing on the following fields of study:

Her primary areas of study are Breast cancer, Internal medicine, Oncology, Prospective cohort study and Hazard ratio. Her Breast cancer study deals with the bigger picture of Cancer. Her Internal medicine research is multidisciplinary, relying on both Mutation, MEDLINE and Gene, Germline.

Her Oncology research includes elements of Germline mutation, Genome-wide association study, Single-nucleotide polymorphism, Medical genetics and Ovarian cancer. In her study, Cancer research and Human Epidermal Growth Factor Receptor 2 is inextricably linked to Estrogen receptor, which falls within the broad field of Genome-wide association study. Her research in Prospective cohort study intersects with topics in Absolute risk reduction, BRCA2 Mutation, Retrospective cohort study, Natural menopause and Family history.

Between 2018 and 2021, her most popular works were:

  • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes (257 citations)
  • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes (257 citations)
  • Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families (68 citations)

In her most recent research, the most cited papers focused on:

  • Gene
  • Cancer
  • Internal medicine

Her primary scientific interests are in Breast cancer, Internal medicine, Oncology, Prospective cohort study and Cohort study. Breast cancer is a subfield of Cancer that Irene L. Andrulis explores. Her Oncology research includes elements of Odds ratio, Germline mutation, PALB2, Hazard ratio and Prostate cancer.

Irene L. Andrulis has included themes like Absolute risk reduction and Single-nucleotide polymorphism in her Hazard ratio study. Her Prospective cohort study research includes themes of Family history and Obstetrics. Her studies deal with areas such as Incidence, BRCA2 Mutation, Natural menopause, Menopause and Surgical oncology as well as Cohort study.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Karoline B. Kuchenbaecker;Karoline B. Kuchenbaecker;John L. Hopper;Daniel R. Barnes;Kelly-Anne Phillips.
JAMA (2017)

1156 Citations

Large-scale genotyping identifies 41 new loci associated with breast cancer risk

Kyriaki Michailidou;Per Hall;Anna Gonzalez-Neira;Maya Ghoussaini.
Nature Genetics (2013)

1074 Citations

Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.

K. E. Noonan;C. Beck;T. A. Holzmayer;J. E. Chin.
Proceedings of the National Academy of Sciences of the United States of America (1990)

1054 Citations

MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma

Kolja Eppert;Stephen W Scherer;Hilmi Ozcelik;Rosa Pirone.
Cell (1996)

1027 Citations

Breast-Cancer Risk in Families with Mutations in PALB2

A. C. Antoniou;S. Casadei;T. Heikkinen;D. Barrowdale.
The New England Journal of Medicine (2014)

804 Citations

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

Kathleen I. Pritchard;Lois E. Shepherd;Frances P. O'Malley;Irene L. Andrulis.
The New England Journal of Medicine (2006)

698 Citations

Association analysis identifies 65 new breast cancer risk loci

Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley.
Nature (2017)

691 Citations

RAD51B in Familial Breast Cancer

Liisa M. Pelttari;Sofia Khan;Mikko Vuorela;Johanna I. Kiiski.
PLOS ONE (2016)

608 Citations

MicroRNA related polymorphisms and breast cancer risk

Sofia Khan;Dario Greco;Dario Greco;Kyriaki Michailidou;Roger L. Milne;Roger L. Milne.
PLOS ONE (2014)

582 Citations

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.

I L Andrulis;S B Bull;M E Blackstein;D Sutherland.
Journal of Clinical Oncology (1998)

582 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Irene L. Andrulis

Graham G. Giles

Graham G. Giles

University of Melbourne

Publications: 278

Paul D.P. Pharoah

Paul D.P. Pharoah

University of Cambridge

Publications: 180

Melissa C. Southey

Melissa C. Southey

Cancer Council Victoria

Publications: 174

John L. Hopper

John L. Hopper

University of Melbourne

Publications: 174

Douglas F. Easton

Douglas F. Easton

University of Cambridge

Publications: 174

Roger L. Milne

Roger L. Milne

Cancer Council Victoria

Publications: 166

Steven A. Narod

Steven A. Narod

University of Toronto

Publications: 152

Esther M. John

Esther M. John

Stanford University

Publications: 140

Jenny Chang-Claude

Jenny Chang-Claude

German Cancer Research Center

Publications: 135

Wei Zheng

Wei Zheng

Vanderbilt University Medical Center

Publications: 133

Stephen J. Chanock

Stephen J. Chanock

National Institutes of Health

Publications: 133

Peter Kraft

Peter Kraft

Harvard University

Publications: 128

Christopher A. Haiman

Christopher A. Haiman

University of Southern California

Publications: 121

Fergus J. Couch

Fergus J. Couch

Mayo Clinic

Publications: 120

Dominique Stoppa-Lyonnet

Dominique Stoppa-Lyonnet

Institute Curie

Publications: 104

Georgia Chenevix-Trench

Georgia Chenevix-Trench

QIMR Berghofer Medical Research Institute

Publications: 102

Something went wrong. Please try again later.